← All trials
NCT05955391
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2023
- Primary completion
- Feb 28, 2024
- Completion date
- Aug 30, 2024
- First posted
- Jul 21, 2023
- Last posted
- Jul 21, 2023
- Enrollment
- 157
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Guizhou Medical UniversityCollaborator
- Bengbu Medical CollegeCollaborator
- Sun Yat-Sen UniversityCollaborator
- Jiao Tong UniversityCollaborator
- China Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Henan Medical UniversityCollaborator
- Central South UniversityCollaborator
- Jiangxi Provincial Cancer HospitalCollaborator
- Jilin Provincial Tumor HospitalCollaborator
- Dalian Medical UniversityCollaborator
- Mianyang Central HospitalCollaborator
- Ningbo No. 1 HospitalCollaborator
- Shandong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
- Sun Yat-Sen UniversityCollaborator
- Qingdao UniversityCollaborator
- Zhengzhou UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Sichuan UniversityCollaborator
- Central South UniversityCollaborator
- Cancer Hospital of Yunnan provincealCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Zhejiang UniversityCollaborator
- Shijiazhuang People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.